High-Dose Vitamin C and Survival in Advanced Cancer:
Revisiting the 1976 Cameron and Pauling Study
In 1976, Ewan Cameron and Linus Pauling published a study in Proceedings of the National Academy of Sciences of the United States of America examining whether supplemental high-dose ascorbate was associated with survival time in patients with advanced cancer.
The study extended Cameron’s earlier clinical observations on high-dose vitamin C and later became one of the most frequently cited early publications in the history of vitamin C and cancer research.
What Did the Study Do?
The study included 100 patients with terminal cancer and compared their survival with 1,000 clinically similar control patients who did not receive supplemental ascorbate.
Received supplemental ascorbate in addition to routine medical management.
100
1,000
This was not a modern randomized controlled trial.
Matched
Non-RCT
What Did the Study Observe?
The study reported that the 100 patients receiving supplemental ascorbate had a mean survival time of more than 210 days, compared with approximately 50 days in the control group.
The authors therefore reported that the average survival time in the ascorbate group was more than 4.2 times that of the control group.
These findings attracted considerable attention at the time and helped stimulate further research into high-dose vitamin C in the field of cancer.
>210 days
Mean Survival Time
~50 days
The Authors Reported an Approximate 4.2-Fold Difference in Mean Survival
This was an observational finding within a non-randomized matched-control study. It should not be interpreted as definitive proof that high-dose vitamin C itself caused the observed survival difference.
How Should This Study Be Interpreted?
Although the reported survival difference was substantial, the study has important limitations when assessed according to modern evidence-based medicine standards.
Most importantly, patients were not randomly allocated, and the control group was not generated through a concurrent randomized process. Even though the investigators attempted to select clinically similar controls, differences in patient selection, disease severity, previous medical management, and other unmeasured factors may have influenced the results.
An Early Clinical Signal Is Not the Same as Established Benefit
The study can reasonably be viewed as an early clinical observation that warranted further investigation, but it cannot by itself establish that high-dose vitamin C prolongs survival in patients with cancer.
What Did Later Studies Find?
Following the Cameron and Pauling reports, researchers conducted more rigorous randomized trials and later pharmacokinetic studies to investigate high-dose vitamin C further.
Mayo Clinic Studies
Among the best-known subsequent trials were Mayo Clinic studies using high-dose oral vitamin C, which did not reproduce a clear survival advantage.
Intravenous and Oral Vitamin C Are Not Pharmacokinetically Equivalent
Later pharmacokinetic research demonstrated that intravenous administration can produce much higher blood ascorbate concentrations than oral dosing. Current NCI information therefore distinguishes intravenous from oral exposure.
The Current Evidence Is More Complex Than the Early Reports Suggested
The Cameron and Pauling study generated an important early clinical signal, but subsequent evidence has not established that high-dose vitamin C universally prolongs survival in patients with cancer.
How Does BMS Clinic View This Evidence?
Evidence-Based · Personalised Assessment
For patients with cancer, a positive finding from an early study should not be interpreted in isolation as established clinical benefit.
High-dose intravenous vitamin C is also not equivalent to routine oral vitamin supplementation. Its use requires consideration of the patient’s cancer type, current disease status, ongoing medical management, kidney function, G6PD status, and other individual risk factors.
BMS Clinic emphasizes individualized assessment based on the available medical evidence. Any supportive medical approach should be considered alongside the patient’s existing cancer care rather than replacing comprehensive clinical judgment with the result of a single study.
The information on this page is provided for medical education and literature reference purposes only. It is intended to help readers understand the 1976 Cameron and Pauling study on high-dose Vitamin C and survival in patients with advanced cancer, and is not a substitute for assessment or advice from a doctor or other qualified healthcare professional.
This study was an early non-randomized clinical comparative study and was subject to limitations related to study design, patient differences and other factors. Its findings alone do not establish that high-dose Vitamin C can prolong survival in patients with cancer or improve cancer prognosis.
Cancer patients considering high-dose intravenous Vitamin C or other forms of supportive medical care should undergo an individualized assessment by a qualified healthcare professional based on their medical condition, current medical management, kidney function, G6PD status and other relevant risk factors.
Learn More About High-Dose Vitamin C Medical Support
High-dose intravenous Vitamin C is different from conventional oral vitamin supplementation, and its suitability for an individual patient cannot be determined solely on the basis of early research findings. If you would like to learn more about the relevant medical evidence, clinical considerations and individual suitability, a professional medical assessment is recommended.
References
Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1976;73(10):3685–3689.
National Cancer Institute. Intravenous Vitamin C (PDQ®)–Health Professional Version. National Cancer Institute.